24 Oct 2025 | 5 Mins Read
Syngene expands biologics facility with ADC bioconjugation
Flipitmoney
Syngene International Ltd expanded its biologics facility with new ADC bioconjugation capabilities, providing end-to-end services from discovery to GMP manufacturing. The investment complements existing commercial payload and linker manufacturing capabilities. Revenue increased 10.7% to ₹874.5 crore in Q2, with a 210 basis point EBITDA margin expansion to 23.6%. Shares rose 3% to ₹661.10.